Literature DB >> 9279255

Effect of upper respiratory tract infection in patients with neuromuscular disease.

J M Poponick1, I Jacobs, G Supinski, A F DiMarco.   

Abstract

Respiratory muscle strength during acute upper respiratory tract infection (URI) was assessed in patients with various forms of neuromuscular disease. Vital capacity (VC), oxygen saturation, end-tidal PCO2, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) were determined in 25 stable patients with various forms of neuromuscular disease. Thirteen episodes of URI developed in 10 patients. Respiratory parameters were reassessed within 24-36 h following the onset of symptoms in each patient. In patients with URI, mean baseline VC, MIP, and MEP were 1.16 L +/- 0.14, 49.2 cm H2O +/- 6.8, and 35.5 cm H2O +/- 3.8 and fell to 1.01 L +/- 0.15, 37.1 cm H2O +/- 6.2, and 25.5 cm H2O +/- 3.0 during URI (p < 0.05 for each), respectively. Mean baseline PCO2 and oxygen saturation were 39.1 mm Hg +/- 1.1 and 95.1% +/- 1.0, and during URI, 43.9 mm Hg +/- 2.1 (p < 0.05) and 95.0% +/- 1.0 (NS), respectively. Five episodes of significant hypercapnia were observed in 4 patients. All parameters returned to near baseline values following recovery. We conclude that patients with various forms of neuromuscular disease develop reductions in respiratory muscle strength in association with URI. Unlike normal subjects, however, these decrements in respiratory muscle function may result in symptoms of shortness of breath, reductions in vital capacity, and acute hypercapnia in this patient population.

Entities:  

Mesh:

Year:  1997        PMID: 9279255     DOI: 10.1164/ajrccm.156.2.9611029

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  17 in total

1.  Double-stranded RNA-dependent protein kinase activation modulates endotoxin-induced diaphragm weakness.

Authors:  G S Supinski; L A Callahan
Journal:  J Appl Physiol (1985)       Date:  2010-11-11

2.  Intrapulmonary percussive ventilation in tracheostomized patients: a randomized controlled trial.

Authors:  Enrico M Clini; Francesca Degli Antoni; Michele Vitacca; Ernesto Crisafulli; Mara Paneroni; Sheila Chezzi-Silva; Maurizio Moretti; Ludovico Trianni; Leonardo M Fabbri
Journal:  Intensive Care Med       Date:  2006-10-24       Impact factor: 17.440

3.  Critical diaphragm failure in sudden infant death syndrome.

Authors:  Pontus Max Axel Siren; Matti Juhani Siren
Journal:  Ups J Med Sci       Date:  2011-01-12       Impact factor: 2.384

4.  The JNK MAP kinase pathway contributes to the development of endotoxin-induced diaphragm caspase activation.

Authors:  Gerald S Supinski; Xinying Ji; Leigh Ann Callahan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-15       Impact factor: 3.619

5.  Eicosapentaenoic acid preserves diaphragm force generation following endotoxin administration.

Authors:  Gerald S Supinski; Jonas Vanags; Leigh Ann Callahan
Journal:  Crit Care       Date:  2010-03-16       Impact factor: 9.097

6.  p38 Mitogen-activated protein kinase modulates endotoxin-induced diaphragm caspase activation.

Authors:  Gerry S Supinski; Xin-ying Ji; Leigh Ann Callahan
Journal:  Am J Respir Cell Mol Biol       Date:  2009-08-28       Impact factor: 6.914

7.  Calpain activation contributes to endotoxin-induced diaphragmatic dysfunction.

Authors:  Gerald S Supinski; Leigh Ann Callahan
Journal:  Am J Respir Cell Mol Biol       Date:  2009-03-27       Impact factor: 6.914

8.  Respiratory Failure or Impairment in Amyotrophic Lateral Sclerosis.

Authors:  Deborah F. Gelanis
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.972

9.  Mechanical insufflation-exsufflation: Practice patterns among respiratory therapists in Ontario.

Authors:  Shelley Prevost; Dina Brooks; Phillip T Bwititi
Journal:  Can J Respir Ther       Date:  2015

Review 10.  Disorders of Sleep and Ventilatory Control in Prader-Willi Syndrome.

Authors:  Emily S Gillett; Iris A Perez
Journal:  Diseases       Date:  2016-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.